Clinical trials
Leukemia, Lymphocytic, Chronic, B-Cell clinical trials
Below are recruiting leukemia, lymphocytic, chronic, b-cell clinical trials, each written for real people, not researchers. We’re tracking 132 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06364423RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive leukemias and lymphomas
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
Bethesda, MarylandAges 18–120 - NCT06415708RecruitingPhase 2
Obinutuzumab with bendamustine for B-cell lymphoma
This trial tests a combination of two drugs—obinutuzumab and bendamustine—for people with certain B-cell lymphomas that haven't been treated before. The goal is to see how well this combination works and how safe it is.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06514768RecruitingEarly Phase 1
JY231 injection for B-cell acute lymphoblastic leukemia
This trial tests a new injection (JY231) for people with B-cell acute lymphoblastic leukemia (B-ALL) that has not responded well to treatment or has come back. It aims to see if the treatment can help reduce cancer cells in the bone marrow.
Kunming, YunnanAges Up to 75 years - NCT06520098RecruitingPhase 2
BTK inhibitor with or without venetoclax for CLL/SLL
This trial tests whether adding venetoclax to your current BTK inhibitor (like ibrutinib, acalabrutinib, or zanubrutinib) works better than taking the BTK inhibitor alone. It's for veterans with CLL or SLL who have been on a BTK inhibitor for at least six months and have not had their disease get worse on that therapy.
San Francisco, CaliforniaAges 18–80 - NCT06528301RecruitingPhase 1
Trial of UB-VV111 with or without rapamycin for B-cell cancers
This trial tests a new therapy called UB-VV111, alone or with rapamycin, in people with certain types of lymphoma or leukemia that have come back or not responded to treatment. The goal is to see if it's safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Minneapolis, MinnesotaAges 18 years+ - NCT06536452Recruiting
How blood cell production differs in CLL, MBL, and healthy people
This trial studies how the body makes blood cells in people with chronic lymphocytic leukemia (CLL), a related condition called monoclonal B-cell lymphocytosis (MBL), and in healthy volunteers matched by age. The goal is to understand differences that may help improve treatment or monitoring.
Rochester, MinnesotaAges 40 years+ - NCT06593145RecruitingPhase 1
CAR-T therapy for relapsed CD19+ B-cell cancers
This trial tests a new type of CAR-T cell therapy for people with certain B-cell cancers (leukemia or lymphoma) that have not responded to standard treatments. It aims to see if these specially engineered immune cells can attack and destroy the cancer.
Warsaw, Ul. Banacha 1aAges 18–65 - NCT06644183RecruitingPhase 1/Phase 2
Triple therapy for relapsed CLL after prior treatments
This trial tests three drugs—roginolisib, venetoclax, and rituximab—for people with CLL that has come back or not responded after at least two prior treatments, including a BTK inhibitor. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06659653RecruitingEarly Phase 1
PRG-2302 for relapsed or hard-to-treat B-cell acute lymphoblastic leukemia
This trial tests a new drug called PRG-2302 for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not responded to standard treatments. The goal is to see if PRG-2302 is safe and can help control the disease.
Jinzhou, HubeiAges 18–70 - NCT06693830Recruiting
Blood test guided treatment for newly diagnosed DLBCL
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
New York, New YorkAges 18 years+ - NCT03501576Recruiting
Testing a flu or COVID vaccine response in people with lymphoma
This study checks how your immune system responds after getting a vaccine. It focuses on people with different types of lymphoma, aiming to learn which immune responses can be measured and whether the vaccines are safe for you.
Atlanta, GeorgiaAges 18 years+ - NCT06712810RecruitingPhase 1
Q702 for blood cancers and histiocytic disorders
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06784167Recruiting
Vaccine response after CAR-T for myeloma and lymphoma
This study looks at how well vaccines work in people with multiple myeloma or certain lymphomas after they receive CAR-T cell therapy. It aims to help doctors understand the best way to revaccinate patients to protect against preventable diseases.
Portland, OregonAges 18 years+ - NCT06812715RecruitingPhase 2
Pirtobrutinib after zanubrutinib for chronic lymphocytic leukemia
This trial tests a new drug, pirtobrutinib, for people with chronic lymphocytic leukemia (CLL) who have already been treated with zanubrutinib (a similar BTK inhibitor). The goal is to see if switching to pirtobrutinib can help control the disease.
Melbourne, VictoriaAges 18 years+ - NCT06820268RecruitingPhase 1
XS-04 for blood cancers that returned after treatment
This study tests a new drug, XS-04, for people with certain blood cancers (like B-cell lymphoma, AML, or MDS) that have come back or not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors or control the disease.
BeijingAges 18–75 - NCT06859008RecruitingPhase 1
Zanubrutinib and sonrotoclax for B-cell lymphoma in diverse groups
This trial tests two targeted drugs, zanubrutinib and sonrotoclax, together for people with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It focuses on enrolling patients from racial and ethnic groups that are often underrepresented in research.
Duarte, CaliforniaAges 18 years+ - NCT06961669Recruiting
CD19 CAR-T cells for B-cell cancers and multiple myeloma
This trial tests a personalized treatment where your own immune cells are modified to target and kill cancer cells that have a protein called CD19. It is for patients with certain types of B-cell lymphoma, B-cell acute leukemia, or multiple myeloma that has come back or not responded to previous treatment.
HefeiAges 3 years+ - NCT06980116RecruitingPhase 1
Finding the right dose of EXS73565 for relapsed B-cell cancers
This study tests a new oral medication (EXS73565) for people with B-cell blood cancers that came back or didn't respond to standard treatments. It aims to find the best dose and check if it's safe and helpful.
TbilisiAges 18 years+ - NCT07030400Recruiting
Quality of life study for adults with CLL or SLL
This study looks at how health-related quality of life changes in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when starting a new treatment. The goal is to better understand what affects well-being during therapy.
Tampa, FloridaAges 18 years+ - NCT07078500RecruitingPhase 2
Orelabrutinib plus Pola-R-CHP for untreated non-GCB DLBCL
This trial tests a combination of targeted therapy (Orelabrutinib) plus standard chemotherapy (Pola-R-CHP) for people with untreated non-GCB diffuse large B-cell lymphoma. The goal is to see if this new mix works better than the usual treatment.
Hangzhou, ZhejiangAges 18–80 - NCT07125872RecruitingPhase 2
New drug for relapsed B-cell lymphoma
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
JohannesburgAges 18 years+ - NCT07189065RecruitingPhase 2
Rocbrutinib for relapsed or refractory non-GCB DLBCL
This trial tests a new targeted therapy, Rocbrutinib, for a specific type of aggressive B-cell lymphoma (non-GCB DLBCL) that has not responded to or returned after two or more prior treatments. It aims to see if Rocbrutinib can help people who have few other options.
Hefei, AnhuiAges 18 years+ - NCT07205315RecruitingEarly Phase 1
Testing GT801 cell therapy for blood cancer and AIHA
This study tests an investigational cell therapy called GT801 for people whose CD19-positive blood cancer (B-ALL, CLL, or B-NHL) or autoimmune hemolytic anemia (AIHA) has not responded to standard treatments. The therapy is made from your own immune cells, modified to target and destroy cancer cells or abnormal immune cells.
Zhengzhou, HenanAges 18–75
Hear when a new Leukemia, Lymphocytic, Chronic, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia, lymphocytic, chronic, b-cell?
- Yes. Clin2 currently lists 132 recruiting leukemia, lymphocytic, chronic, b-cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia, lymphocytic, chronic, b-cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia, lymphocytic, chronic, b-cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.